Metformin Efficacy and Safety in Epileptic Patients

• Status: Recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is:

• Does metformin have beneficial effect on epileptic patients?

• How metformin can affect epileptic patient's health?

Participants will be divided into 2 groups (control group and treatment group)

• Control group will receive standard treatment (levetiracetam).

• Treatment group will receive standard treatment (levetiracetam) + metformin

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Levetiracetam; Metformin

Criteria

Inclusion Criteria:

• Age: 18 - 65 years old

• Obese and overweight patients with body mass index (BMI) ≥ 25.

Exclusion Criteria:

• Patients with severe liver damage or kidney disease (eGFR below 45mL/min/1.73 m²).

• Patients having acute or chronic disease which may cause tissue hypoxia and increase the risk of lactic acidosis (e.g. cardiac/respiratory failure, recent myocardial infarction).

• Patients who are already taking metformin.

• Diabetic patients.

• Cancer patients.

• Pregnant or lactating women.

• Patients with known hypersensitivity to the drug.